At the European Society of Medical Oncology (ESMO) 2025 Congress in Berlin, BeOne Medicines announced new data from two pivotal Phase 3 trials of its PD-1 inhibitor TEVIMBRA, showing enduring efficacy across multiple lung cancer subtypes, and unveiled the first clinical results of its investigational HPK1 inhibitor in advanced solid tumors.
An especially significant outcome was the reported overall survival benefit of TEVIMBRA plus chemotherapy for squamous non-small cell lung cancer...
English (US) ·